ArticleTechnical innovations & patient support in radiation oncology2023
Investigating the feasibility of using Ethos generated treatment plans for head and neck cancer patients.
Article in Technical innovations & patient support in radiation oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Transfer of fractionated treatment plans from ring-gantry to L-shaped linacs using fluence map convolution.Physical and engineering sciences in medicine · 2026Article
- Initial experience of clinical implementation of an Online Simulation-free CBCT-based Adaptive Radiotherapy (OSCAR) workflow for palliative and urgent treatment indications.Journal of applied clinical medical physics · 2026Article
- Best Practice: CT-guided Adaptive Radiotherapy Reference Planning on the Ethos Platform.Journal of applied clinical medical physics · 2026Review
- Solution for the hot spots in adaptive radiotherapy planning for cervical cancer: a case report and review of literature.Frontiers in oncology · 2026Article
- Advanced HyperSight™ imaging for patients with adaptive SBRT of prostate cancer: a longitudinal analysis of tissue demarcation.Radiation oncology (London, England) · 2025Article
- Article
- Article
- Towards Automation in Radiotherapy Planning: A Deep Learning Approach for the Delineation of Parotid Glands in Head and Neck Cancer.Bioengineering (Basel, Switzerland) · 2024Article
- Evaluation of Ethos intelligent optimization engine for left locally advanced breast cancer.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Varian Ethos treatment platform is designed to automatically create complex RT treatment plans, reducing both workload and operator variability in plan quality. The aim of this study is to evaluate the quality of Ethos-generated head and neck (H&N) treatment plans. Ethos plans were created for ten previous H&N patients and these were compared with the original clinical plans generated in Eclipse. Ethos automatically creates several plans with different field arrangements for each patient. All plans were compared quantitatively using: dose-volume metrics; dose conformity; dose heterogeneity and monitor units (MU). In addition, two H&N Oncologists assessed the clinical acceptability of the Ethos plans. Consultant 1 judged there to be at least three clinically acceptable Ethos plans for 9 out of 10 patients reviewed. Consultant 2 approved of at least two Ethos plans for 5 out of 5 patients reviewed. The Ethos plans' average dose metrics were comparable to the clinical plans. The average plan MU was similar for Eclipse and Ethos VMAT plans. The average plan MU for Ethos IMRT plans was larger with respect to all VMAT plans. The Ethos Treatment Planning system is capable of automatically creating good quality treatment plans for a range of H&N cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.